An Investigation of the Anti-Parkinsonism Potential of Co-enzyme Q₁₀ and Co-enzyme Q₁₀ /Levodopa-carbidopa Combination in Mice

Title:An Investigation of the Anti-Parkinsonism Potential of Co-enzyme Q₁₀ and Co-enzyme Q₁₀ /Levodopa-carbidopa Combination in Mice

Volume: 14 Issue: 1

Author(s): Olakunle J. Onaolapo, Ademola O. Odeniyi, Stephen O. Jonathan, Moyinoluwa O. Samuel, Deborah Amadiegwu, Ajoke Olawale, Aisha O. Tiamiyu, Folusho O. Ojo, Hameed A. Yahaya, Oluwadamilare J. Ayeni and Adejoke Y. Onaolapo*

Affiliation:

• Department of Anatomy, Ladoke Akintola University of Technology, Ogbomosho, Oyo State,Nigeria

Keywords: Antioxidant, dopamine, electron transfer chain, neurobehaviour, Parkinson's disease, intraperitoneal.

Abstract:

Background: Despite decades of research, neurodegenerative disorders like Parkinson’s disease remain a leading cause of disability worldwide, due to the insufficient reduction of disease burden by available medications. Recently, the benefits of dietary supplements like co-enzyme Q₁₀ in neurodegenerative diseases have been reported.

Aim: The protective effects of supplemental co-enzyme Q₁₀ (CQ₁₀) and possible additive benefits of CQ₁₀/Levodopa-Carbidopa (LD) in Chlorpromazine (CPZ)-induced Parkinsonism-like changes in mice were investigated.

Methods: Male mice were assigned to ten groups of 30 mice each. Groups included: Vehicle control (fed Standard Diet (SD), and given intraperitoneal {ip} plus oral saline), LD group (fed SD, and given ip saline plus oral LD), two groups fed CQ₁₀-supplemented diet (at 60 and 120 mg/kg of feed), and given ip plus oral saline, CPZ group (fed SD, and given ip CPZ plus oral saline), CPZ/LD group (fed SD, and given ip CPZ plus oral LD), two groups fed CQ₁₀-supplemented diet (at 60 and 120 mg/kg of feed) and given ip CPZ plus oral saline, and another two groups fed CQ₁₀-supplemented diet (at 60 and 120 mg/kg of feed) and given ip CPZ plus oral LD. The total duration of study was 21 days, and treatments were administered daily. Bodyweight and food intake were measured weekly, while neurobehavioural and biochemical tests were assessed at the end of the experimental period.

Results: CQ₁₀-supplementation was protective against CPZ-induced parkinsonism-like changes including, reduction in mortality, the reversal of retardation of open-field behaviours and reduction of catalepsy, increase in dopamine levels and decreased oxidative stress. CQ₁₀ also showed significant improvements in these parameters when co-administered with LD. CQ₁₀ (in groups administered CPZ/CQ₁₀ 60) showed greater benefit over LD on anxiety-related behaviours and also had additive benefits on working-memory.

Conclusion: Dietary CQ₁₀-supplementation was associated with demonstrable benefits in CPZinduced Parkinsonism-like changes in mice.

Cite this article as:

Onaolapo J. Olakunle , Odeniyi O. Ademola , Jonathan O. Stephen , Samuel O. Moyinoluwa , Amadiegwu Deborah , Olawale Ajoke , Tiamiyu O. Aisha , Ojo O. Folusho , Yahaya A. Hameed, Ayeni J. Oluwadamilare and Onaolapo Y. Adejoke *, An Investigation of the Anti-Parkinsonism Potential of Co-enzyme Q₁₀ and Co-enzyme Q₁₀ /Levodopa-carbidopa Combination in Mice, Current Aging Science 2021; 14 (1) . https://dx.doi.org/10.2174/1874609812666191023153724

DOI https://dx.doi.org/10.2174/1874609812666191023153724	Print ISSN 1874-6098
Publisher Name Bentham Science Publisher	Online ISSN 1874-6128